Interim

Cook County Health Celebrates the Launch of New Robotic Surgery Program

Retrieved on: 
Thursday, April 18, 2024
Health equity, Health, Surgeon, Hand, Motion, Patient, Interim, Dentistry

Chicago, IL, April 18, 2024 (GLOBE NEWSWIRE) -- On April 17, Cook County Health cut the ribbon on its Intuitive da Vinci® surgical system, celebrating the health system’s new robotic surgery program.

Key Points: 
  • Chicago, IL, April 18, 2024 (GLOBE NEWSWIRE) -- On April 17, Cook County Health cut the ribbon on its Intuitive da Vinci® surgical system, celebrating the health system’s new robotic surgery program.
  • “In making robotic surgery possible at Stroger Hospital, Cook County Health is demonstrating its commitment to health equity and advancement to ensure patients receive the highest quality of care.”
    The robotic surgery program represents an $11 million investment over seven years to bring the latest surgical technology to Cook County Health.
  • Cook County Health expects to perform more than 500 robotic-assisted surgeries this year, with plans to continue to grow the program year-over-year.
  • For more information about Cook County Health’s robotic surgery program, visit https://cookcountyhealth.org/robotic-assisted-surgery/ .

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, April 17, 2024
Doctor of Philosophy, Immunotherapy, American Academy, NHS, IGNITE, Safety, University College London, AFL, TREM2, American Academy of Neurology, Microglia, Publication, Clinical professor, AAN, ALSP, MRI, Serum, CSF, Interim, Biomarker, Poster, Cerebrospinal fluid, Deficit spending, Medical imaging

WATERTOWN, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the presentation of multiple oral and poster presentations on the Company’s lead clinical candidate iluzanebart at the 2024 American Academy of Neurology (AAN) Annual Meeting.

Key Points: 
  • “We are excited to see our enthusiasm for iluzanebart matched by clinical leaders in the ALSP community.
  • The interim findings from both the IGNITE Phase 2 and ILLUMINATE Natural History studies support the potential of iluzanebart to become the first, disease-modifying therapy for those living with ALSP,” said Petra Kaufmann, M.D., F.A.A.N, Chief Medical Officer of Vigil.
  • “Both trials have led to an incredible step forward – not only in understanding ALSP disease progression, but also in drawing parallels between biomarkers and correlating clinical outcomes.
  • Data on clinical measures, biomarkers, and MRI from ILLUMINATE were presented at the conference.

Sanford Heisler Sharp Files $10 Million Religious & Age Discrimination, Retaliation Suit Against Teachers College, Columbia University for Muslim Faculty Member Denied Tenure - Track Positions

Retrieved on: 
Wednesday, April 17, 2024
Education, Lawyer, ITS, Religion, The Cat, School, Complaint, Columbia University, Bosniaks, Employment, Teachers College, Columbia University, District court, Civil Rights Act, Muslims, Faculty, Ageism, Nadig, Interim, Student, Associate, Employment Act of 1946, Lip, ALL

The Complaint alleges that Teachers College discriminated against Dr. Sabic-El-Rayess, a 48-year-old Muslim woman, by repeatedly denying her a promotion to a tenure-track role because of her Muslim religion and age.

Key Points: 
  • The Complaint alleges that Teachers College discriminated against Dr. Sabic-El-Rayess, a 48-year-old Muslim woman, by repeatedly denying her a promotion to a tenure-track role because of her Muslim religion and age.
  • Dr. Sabic-El-Rayess is represented by Sanford Heisler Sharp’s Chairman David Sanford, Partner Melinda Koster, and Senior Litigation Counsel Alok Nadig, as well as Deborah Rhode Civil Rights Fellow Hoda Katebi.
  • “Teachers College’s mistreatment of Dr. Sabic-El-Rayess demonstrates that it is paying lip service to its professed values of diversity and inclusion,” said Sanford.
  • For example, when Dr. Sabic-El-Rayess applied for a tenure-track position in 2012, a Hiring Committee member probed into her Muslim background.

Canadian Goldcamps Announces Board and Management Changes

Retrieved on: 
Wednesday, April 17, 2024
Prospectors, University, CFO, Developer, OTC, A68, CPA, Gold, Interim, MBA, Mining, Management

TORONTO, April 17, 2024 (GLOBE NEWSWIRE) -- Canadian GoldCamps Corp. (“Canadian GoldCamps”, or the “Company”) (CSE: CAMP) (FSE: A68) (OTC: SMATF) announces that Brendan Purdy has resigned as a director and interim CEO effective immediately.

Key Points: 
  • TORONTO, April 17, 2024 (GLOBE NEWSWIRE) -- Canadian GoldCamps Corp. (“Canadian GoldCamps”, or the “Company”) (CSE: CAMP) (FSE: A68) (OTC: SMATF) announces that Brendan Purdy has resigned as a director and interim CEO effective immediately.
  • Newly appointed to the Board are Jason Hawkins and Mike Taylor.
  • Mr. Taylor has also been appointed Interim Chief Executive Officer and Kevin Cornish has been appointed Chief Financial Officer, effective immediately.
  • Mr. Cornish has held not for profit, private and public company board and CFO positions throughout his career.

Millicom’s Nomination Committee’s proposal for Board of Directors

Retrieved on: 
Wednesday, April 17, 2024
Millicom, Annual, Treasury, Atlas, Mauricio Ramos, Chairperson, Southeastern Asset Management, Committee, Nomination, Interim, Telecommunications, AGM

Pernille Erenbjerg and Michael Golan have decided not to seek re-election.

Key Points: 
  • Pernille Erenbjerg and Michael Golan have decided not to seek re-election.
  • Aude Durand, Chair of the Nomination Committee, commented: “The Nomination Committee is pleased to propose the election of Maxime Lombardini and Justine Dimovic as new Board Directors.
  • The addition of these new directors will strengthen Board’s oversight of Millicom’s operational and financial performance and of its capital allocation and strategic direction.”
    Mauricio Ramos, Chair of the Board, added: “On behalf of the Board, the management team, and all shareholders, I would like to extend our gratitude to our outgoing directors for their significant contributions to the Board.
  • Since his appointment in May 2023, Michael Golan contributed significantly to Millicom’s restructuring program and oversight of financial matters while serving on Millicom’s Audit and Compliance Committee.

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 16, 2024
Mergers and acquisitions, Fertility, Clinic, IVC, Acquisition, Regenerative medicine, Interim, Adjustment, Bank statement, GAAP, Growth, Pharmaceutical industry

All reported clinic revenue is derived from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin which are consolidated in the Company's financial statements.

Key Points: 
  • All reported clinic revenue is derived from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin which are consolidated in the Company's financial statements.
  • Included in the Q4 2023 operating expenses were approximately $250,000 pertaining to the definitive merger agreement with NAYA Biosciences, Inc. ("NAYA") to acquire NAYA in an all-stock transaction.
  • All reported clinic revenue is derived from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin which are consolidated in the Company's financial statements.
  • Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Retrieved on: 
Tuesday, April 16, 2024
Zebra, LLP, Prior, News, Pomerantz, Audit committee, Interim, Bank statement, Therapy, Audit

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA).

Key Points: 
  • NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA).
  • The investigation concerns whether Zevra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME 

Retrieved on: 
Tuesday, April 16, 2024
CFO, LLP, Prior, News, Interim management, Pomerantz, SVP, Senior, Interim, Zymeworks

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Retrieved on: 
Tuesday, April 16, 2024
Natural killer T cell, IP, IPF, KIPO, GRI, Doctor of Philosophy, Idiopathic disease, NKT, RAR, Patent, Retinoic acid, Oxygen, Liver, Patient, Treatment, Movement, Idiopathic pulmonary fibrosis, Interim, Pharmaceutical industry

LA JOLLA, CA, April 16, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, "Prevention and Treatment of Inflammatory Conditions."

Key Points: 
  • The issued patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in the prevention and treatment of inflammatory conditions of the liver.
  • “We are pleased to add this Korea patent to our intellectual property portfolio covering our innovative pipeline of NKT cell modulators.
  • Each granted patent provides further validation and bolsters our confidence of our differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases.
  • For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com .

Exela Technologies, Inc. to Host Fourth Quarter 2023 and Full Year 2023 Financial Results Conference Call

Retrieved on: 
Monday, April 15, 2024
Exela Technologies, Interim

IRVING, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ:XELA, XELAP), a global business process automation (“BPA”) leader, will host a conference call with the financial community to discuss results for the fourth quarter and full year 2023 at 4:30 p.m.

Key Points: 
  • IRVING, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ:XELA, XELAP), a global business process automation (“BPA”) leader, will host a conference call with the financial community to discuss results for the fourth quarter and full year 2023 at 4:30 p.m.
  • ET on April 17, 2024.
  • Hosting the call and reviewing the results will be Par Chadha, Executive Chairman, and Matt Brown, Interim Chief Financial Officer.